Vol 25, No 9 (2025)

Background:Hepatocellular Carcinoma (HCC) is a highly prevalent cancer worldwide, necessitating effective treatment options. However, current treatments do not provide satisfactory results. Quinacrine, a synthetic drug belonging to the 9-aminoacridine family, has demonstrated promising antitumor effects.

Objective:The objective of the current study is to evaluate the anti-HCC effect of Quinacrine and explore whether quinacrine can improve the anti-HCC response of lenvatinib in vitro and in vivo.

Methods:The HepG2 and MHCC-97H cells were treated with Quinacrine. Cell proliferation and cell apoptosis were assessed using the Cell Counting Kit-8 (CCK8) Assay, Colony Formation Assay, and Annexin V/7-AAD staining method. The invasion and migratory ability of HepG2 and MHCC-97H cells were assessed by Transwell Assay. The level of ROS of HCC cells was measured using a ROS-kit by Flow cytometric analysis. Besides, an in vivo study was performed in the Balb/c nude mice bearing MHCC-97H tumors to analyze the function of Quinacrine in tumor growth.

Results:Quinacrine can decrease cell viability in HepG2 and MHCC-97H cells, but not affect LO2 cells. Quinacrine impaired the colony formation, invasion and migratory ability in half-maximal inhibitory concentration (IC50). Quinacrine also significantly induced apoptosis in HepG2 and MHCC-97H cells in a concentrationdependent manner. On the one hand, ROS was significantly up-regulated in HCC cells after quinacrine treatment. On the other hand, We found quinacrine blocked autophagy flux in HepG2 and MHCC-97H cells. Moreover, Quinacrine significantly enhances the anti-HCC efficacy of lenvatinib in vitro. In the mouse MHCC-97H model, We found that combination therapy with Quinacrine and lenvatinib resulted in a smaller tumor volume and weight than inoculated with lenvatinib alone.

Conclusion:Our findings demonstrated that quinacrine exerts anti-HCC effects and sensitizes hepatocellular carcinoma to lenvatinib. Collectively, our study provides novel therapeutic insights for managing HCC and offers a valuable strategy for future clinical interventions in this field.

Background:Irisquinone, an important compound extracted from Semen Irisis, has been used clinically as a radiotherapy sensitizer for lung, oesophageal, head and neck, breast and leukemia cancers. However, the mechanism by which it acts against cancer is still unclear.

Objective:The present study aims to investigate the anti-tumor activity and mechanism of Irisquinone.

Methods:The effect of Irisquinone on cell viability and proliferation was evaluated using the CCK-8 assay. Fluorescence probe (Fast-TRFS) and DTNB assay were used to observe the inhibitory effect of Irisquinone on both intracellular and extracellular thioredoxin reductase (TrxR). The level of reactive oxygen species (ROS) in tumor cells was assessed using the DCFH-DA probe. Annexin V-FITC/PI, staining and microscopy experiments, were used to examine the apoptosis and pyroptosis. Western blotting analyses confirmed that Irisquinone induced apoptosis and pyroptosis in cancer cells by inhibiting TrxR to increase ROS generation

Results:Our research has shown that Irisquinone has anti-proliferative effects on several cancer cell lines while having low toxicity to normal cells. The amount of ROS induced by inhibition of TrxR activated the BAX (proapoptotic protein) and caspase-1(the pro-pyroptotic protein) to induce apoptosis and pyroptosis.

Conclusion:Irisquinone showed anticancer activity through inhibiting TrxR. These results suggested that Irisquinone will be developed to be an anti-tumor drug possibility.

Background:Xanthene derivatives are a notable class of heterocyclic compounds widely studied for their significant biological impact. These molecules, found in both natural and synthetic forms, have attracted substantial scientific interest due to their broad spectrum of biological activities. The xanthene nucleus, in particular, is associated with a range of potential pharmaceutical properties, including antibacterial, antiviral, antiinflammatory, anticancer, and antioxidant effects. Their structural flexibility allows for modifications that can enhance specific biological functions, making them valuable candidates in medicinal chemistry and drug development.

Objective:Multi-component reactions involving two equivalents of 5,5-dimethylcyclohexane-1,3-dione with aromatic aldehydes yield xanthene derivatives that are known for their biological activity. Additionally, fused xanthene derivatives are formed through subsequent heterocyclization reactions, resulting in compounds with a broad range of biological properties.

Methods:Various xanthene derivatives incorporating thiophene and thiazole moieties were synthesized. Compounds 3a-c were further subjected to heterocyclization reactions to produce fused xanthene derivatives with additional heterocyclic components, enhancing their biological activity. The cytotoxic effects of the synthesized compounds were assessed across six cancer cell lines. Inhibition studies on c-Met kinase and the PC-3 cell line were conducted.

Results:Additionally, the compounds' inhibitory activity against tyrosine kinases was evaluated, and morphological changes in the A549 cell line were observed with the two most potent compounds.

Conclusion:The synthesized heterocyclic compounds, derived from 5,5-dimethylcyclohexane-1,3-dione and related cyclohexanone derivatives, exhibited significant inhibitory effects across various cancer cell lines. Specifically, compounds 3b, 5c, 5d, 7b, 7c, 7d, 9a, 9b, 10b, 10c, 12c, 15b, 15c, 16b, 16c, 17c, 17d, 17e, and 17f demonstrated high levels of inhibition, indicating potential for further exploration of xanthene-based heterocyclic compounds to enhance anticancer properties.